ABBV vs MSFT: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and Microsoft Corporation — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-29.
AbbVie Inc. · Healthcare
$197.69
+6.3% upside to fair value
Grade C
High Quality
VS
Microsoft Corporation · Technology
$429.25
-1.3% upside to fair value
Grade B
High Quality
QuantHub Verdict
ABBV has more upside to fair value
(+6.3%).
MSFT trades at a lower forward P/E
(26.8x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
MSFT |
| Current Price |
$197.69 |
$429.25 |
| Fair Value Estimate |
$210.22 |
$423.82 |
| Upside to Fair Value |
+6.3%
|
-1.3%
|
| Market Cap |
$349.7B |
$3,187.4B |
| Forward P/E |
83.3x
|
26.8x
|
| EV / EBITDA |
23.4x
|
17.2x
|
| Price / Sales |
5.7x
|
10.4x
|
| Price / FCF |
18.7x
|
41.2x
|
| Revenue Growth YoY |
+10.0%
|
+16.7%
|
| Gross Margin |
70.2%
|
68.6%
|
| Operating Margin |
26.7%
|
46.7%
|
| Return on Equity |
-361.6%
|
33.6%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
5.35%
|
2.43%
|
| Analyst Consensus |
Strong Buy
|
Strong Buy
|
Investment Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition. Despite a high trailing and forwa…
Microsoft Corporation is a leading technology company specializing in software infrastructure, cloud computing, and productivity solutions. The company benefits from a high-quality business model characterized by durable competitive moats including strong switching costs and intangible assets such as its brand and cloud infrastructure. Under CEO Satya Nadella's leadership since 2014, Microsoft ha…
Accumulation Zones
| Metric |
ABBV |
MSFT |
| Zone Low |
$157.66 |
$317.87 |
| Zone High |
$178.69 |
$360.25 |
| In Buy Zone? |
No
|
No
|